DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for testicular disease — screening already-approved drugs against its 27-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTesticular disease maps to a 27-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for testicular disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glucokinase regulator (GCKR) — GCKR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet f1pdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4BB9 · 1.47 Å · ligand 1-O-phosphono-beta-D-fructopyranose (F1P). Experimental structure, not a prediction.
What the evidence adds up to
Testicular fibrosis is described as a chronic, progressive condition involving excessive deposition of extracellular matrix proteins, leading to fibrotic remodelling, tissue damage, and irreversible loss of male reproductive function. The 2024 review emphasises that no comprehensive synthesis currently exists that systematically covers pathology, diagnosis, pathogenesis, and treatment across related diseases, and it calls for future research and clinical interventions without presenting any trial data or therapeutic outcomes.
For testicular masses, a 2019 review confirms that more than 90% of palpable nodules are malignant germ cell tumours, making radical orchiectomy the standard of care. However, high-frequency ultrasonography now detects small non-palpable lesions that are benign in 60–80% of cases, and the review concludes that testis-sparing surgery is safe and feasible in selected patients: monorchid individuals, those with bilateral masses, and normal patients with small non-palpable lesions up to 3 cm and not exceeding 30% of organ volume. The evidence base is weak — only fourteen retrospective studies met inclusion criteria, no prospective randomised trials exist in Medline, and the authors explicitly temper enthusiasm given the small patient numbers and absence of prospective data.
A 2003 comparative genomics study sequenced 735 distinct hamster testis cDNAs and identified eight previously uncharacterised human genes, including a new kinesin superfamily member and a SET/MYND-domain protein, all expressed primarily in testis. This work is purely descriptive and offers no clinical application. A 2020 thesis on SOX9 targets in mammalian testis development reports that a novel gene regulating testicular cell growth was identified in human testicular cells, providing a new target for genetic screening in undiagnosed disorders of sex development, but again no therapeutic intervention is tested.
A 2013 prospective study of 50 children with imperfect descent of testis found the condition most common at ages 2–5 years, right-sided predominance, and superficial pouch as the most common palpable site. The authors recommend waiting until one year of age for spontaneous descent, orchidopexy within two years because histopathological changes begin at that age and become irreversible by 16, and state that routine preoperative imaging with ultrasound or MRI does not localise a truly non-palpable testis and does not alter surgical management, so laparoscopy should be used directly. Broader context from 2007 and 2008 sources notes testis cancer is rare but curable with prompt referral, with germ cell tumours the most common malignancy in men aged 25–35 and a second peak at 55–65, and around 800 annual UK cases; a 2020 historical overview of the North American Testis Workshop adds no clinical data.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Andrology · 2024 · 17 citations · open access
Testicular fibrosis pathology, diagnosis, pathogenesis, and treatment: A perspective on related diseases
AbstractTesticular fibrosis is a chronic and progressive condition characterized by the excessive deposition of extracellular matrix proteins. This process leads to fibrotic remodeling, damage to testicular tissue, and the irreversible loss of male reproductive function. However, there is currently a lack of comprehensive reviews systematically elucidating the pathology, diagnosis, pathogenesis, and treatment of testicular fibrosis from the perspectives of different related diseases. This review addresses these aspects of testicular fibrosis, with a particular emphasis on elucidating the underlying mechanisms of testicular cells. It provides insights that can be relevant for future research and clinical interventions.
Minerva Urologica e Nefrologica · 2019 · 13 citations
Testis-sparing surgery for testicular masses: current perspectives
AbstractINTRODUCTION: Males who present with a palpable testis nodule are likely to have malignant germ cell tumor in >90% of cases. Therefore radical orchiectomy remains the standard of care for intratesticular tumors. However, due to the recent developments of high-frequency probes in ultrasonography, the incidence of detecting a small non-palpable testis tumor is higher and higher. These lesions are thought to be benign in more than 60-80% of cases, thus a radical orchiectomy should be considered an overtreatment. In addition to that, radical orchiectomy might cause infertility, psychological issues and endocrine disorders, hence an organ-sparing procedure in such cases should be pursued. EVIDENCE ACQUISITION: Only fourteen reliable retrospective studies met the inclusion criteria. No prospective randomized trials have appeared in Medline database. EVIDENCE SYNTHESIS: This review of the current literature has confirmed the safety and efficacy of testicular-sparing surgery in selected patients: 1) monorchid patients; 2) bilateral testis masses; 3) normal patients with a small, non-palpable masses detected with US, as long as the dimension of the lesion is up to 3 cm and not greater that 30% of the total volume of the organ. CONCLUSIONS: According to the literature, testis sparing surgery is a safe and feasible procedure for patients presenting a benign small testis mass. The enthusiasm found in the literature should however be tempered as the small number of patients reported in the studies coupled with the absence of a prospective trial represent important limits that need to be overtaken. Therefore more robust and well-designed studies are needed.
Gene discovery in the hamster: a comparative genomics approach for gene annotation by sequencing of hamster testis cDNAs
AbstractBACKGROUND: Complete genome annotation will likely be achieved through a combination of computer-based analysis of available genome sequences combined with direct experimental characterization of expressed regions of individual genomes. We have utilized a comparative genomics approach involving the sequencing of randomly selected hamster testis cDNAs to begin to identify genes not previously annotated on the human, mouse, rat and Fugu (pufferfish) genomes. RESULTS: 735 distinct sequences were analyzed for their relatedness to known sequences in public databases. Eight of these sequences were derived from previously unidentified genes and expression of these genes in testis was confirmed by Northern blotting. The genomic locations of each sequence were mapped in human, mouse, rat and pufferfish, where applicable, and the structure of their cognate genes was derived using computer-based predictions, genomic comparisons and analysis of uncharacterized cDNA sequences from human and macaque. CONCLUSION: The use of a comparative genomics approach resulted in the identification of eight cDNAs that correspond to previously uncharacterized genes in the human genome. The proteins encoded by these genes included a new member of the kinesin superfamily, a SET/MYND-domain protein, and six proteins for which no specific function could be predicted. Each gene was expressed primarily in testis, suggesting that they may play roles in the development and/or function of testicular cells.
Cleveland Clinic Journal of Medicine · 2007 · 7 citations
Testis cancer: rare, but curable with prompt referral.
AbstractTestis cancer is rare and rapidly progressive but can almost always be cured. Early detection and prompt treatment by an experienced clinician are the cornerstones of successful management. A delay in diagnosis and inadequate or inappropriate treatment increase the risk of death. The author reviews risk factors, diagnostic features, and current treatment.
Cambridge University Press eBooks · 2008 · 0 citations
Testis
AbstractIntroduction The treatment of testicular cancer is a success story for oncology, with high cure rates even for patients with advanced metastatic disease. The management has changed little over the past 20 years, there is a high degree of consensus about treatment, and standard protocols are well developed. Nonetheless, patients with testicular cancer are best managed by specialised multidisciplinary teams. Range of cancers The range of testicular cancers is shown in Table 20.1. Germ cell tumours Incidence and epidemiology The annual incidence of germ cell tumours in the UK is approximately 800 cases. Germ cell tumours are the most common malignant tumours that occur in men between the ages of 25 and 35; there is a second peak between the ages of 55 to 65 years. The reason for the rapid rise in incidence in the Western world is not known. Theories range from the impact of environmental oestrogens, related to oral contraceptive use, to the increased scrotal temperatures resulting from the use of disposable diapers in infancy. Risk factors and aetiology Both genetic and epigenetic factors probably affect the development of testicular cancer. There is certainly a genetic component, with around 2% of cases reporting an affected first-degree relative, and a ten-fold increased relative risk in a brother of an affected relative. However, a range of conditions associated with subnormal testicular development, such as testicular maldescent, Klinefelter's syndrome, Down's syndrome and subfertility, are also associated with a higher risk of cancer.
Celebrating the Silver Anniversary of the North American Testis Workshop
AbstractOBJECTIVE: To provide an overview of the history of the North American Testis Workshop (NATW), of its relationship to the American Society of Andrology (ASA), and of the publications that resulted from the first 25 workshops. METHODS: The collection of volumes and journal articles that relate to the NATW was searched. DISCUSSION AND CONCLUSION: During the first twenty-five meetings of the NATW, a remarkable number of breakthroughs regarding every aspect of the testis were presented. We anticipate that with the acceleration of new genetic, epigenetic, and molecular knowledge of the functions of testicular cells, we will continue to learn about the discovery of new and clinically important aspects of testicular function during the next twenty-five NATWs.
Identification of Novel Targets of SOX9 in Mammalian Testis Development
AbstractThis thesis sought to identify novel genes involved in embryonic testis development. In chromosomally male (or XY) individuals, disruption to genes required for testis formation can result in “Disorders of Sex Development” (DSDs) where ambiguous genitalia or female ovaries arise. However, since the underlying genetic cause remains unknown in about 50% of XY DSDs, clinical management for these patients is compromised. To discover novel testis genes, functional activities of novel candidate factors were tested in human testicular cells. This approach revealed a gene which regulates testicular cell growth, thus providing a new target for genetic screening in undiagnosed DSD cases.
Journal of Evolution of Medical and Dental Sciences · 2013 · 0 citations · open access
CLINICAL STUDY AND MANAGEMENT OF CHILDREN WITH IMPERFECT DESCENT OF TESTIS
AbstractOBJECTIVES: a) To study the different location of the testis in children with imperfect descent of testis, b) To study associated anomalies and complications of imperfect descent of testis, c)To study the various modalities of management of imperfect descent of testis.BACKGROUND DATA: Since the testis originally develops in the abdominal region, its descent may be inhibited anywhere along its normal pathway or it may be diverted from this route in to an ectopic location. This apparently simple developmental anomaly represents one of the more common disorders of the childhood.It affects all races, and there does not seem to be a geographic propensity. undescended testis may be associated with a number of chromosomal and hereditary disorders in which a specific defect can be identified, and complications which are infertility, hernia, trauma are more if left untreated and also interestingis that till today relatively little is known about what cause the testis to migrate from the abdomen in to the scrotum, inspite of research which is going on till now.METHOD: Present study was conducted on 50 patients who presented with complaints of undescended testis and its complications within the age of day 1 of birth to 18 years. It was prospective study and study was done at department of pediatric surgery, Kempegowda institute of medical sciences, Bangalore during study period of December 2011 to May 2013.RESULTS: 1. Imperfect descent of testis is more common in2-5 years of age, 2. Right side is more common followed by left side followed by bilateral, 3. Absence of testis in scrotum with underdeveloped scrotum is the most common complaint, 4. In palpable testis superficial pouch is the most common site where the testis is found. 5. In ectopic femoral is the most common. 6. In impalpable testis most common is canalicular. 6. Gubernacular abnormalities were most common followed by presence of processusvaginalis and hernia sacs. 7. Open orchidopexy for palpable and lap orchidopexy for impalpable testis is the operation performed.CONCLUSION: Many of undescended testis descend within one year of age, hence we should wait till one year of age. Orchidopexy for undescended testis should be done within 2 years of age as histopathological change start from 2 years of age till 16 years where irreversible histopathological changes take place. Retractile testis has no role in surgery and only assurance should be given. Routine preoperative imaging for undescended testis is neither necessary nor helpful. Ultrasound or MRI do not localizes a truenon palpable testis and hence does not alter surgical management. So laparoscopy should be used directly for evaluation of children with impalpable undescended testis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
